Quick Answer
vTv Therapeutics Inc. reported Cash and Equivalents of $88.93 million for fiscal year 2025.
vTv Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $88.93M | +142.0% |
| 2024 | $36.75M | +289.0% |
| 2023 | $9.45M | -22.1% |
| 2022 | $12.13M | -9.6% |
| 2021 | $13.41M | +133.4% |
| 2020 | $5.75M | +223.4% |
| 2019 | $1.78M | +5.6% |
| 2018 | $1.68M | -85.7% |
| 2017 | $11.76M | -77.2% |
| 2016 | $51.51M | -41.5% |
| 2015 | $88.00M | +6258.6% |
| 2014 | $1.38M | +27.1% |
| 2013 | $1.09M | -48.7% |
| 2012 | $2.12M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $98.50M | +137.0% | +280.0% |
| June 30, 2025 | $25.92M | -43.1% | -16.5% |
| March 31, 2025 | $31.06M | -40.6% | -15.5% |
| December 31, 2024 | $36.75M | +289.0% | -11.6% |
| September 30, 2024 | $41.57M | +404.6% | -8.7% |
| June 30, 2024 | $45.53M | +261.3% | -12.9% |
| March 31, 2024 | $52.26M | +178.5% | +453.2% |
| December 31, 2023 | $9.45M | -22.1% | +14.7% |
- vTv Therapeutics Inc. showed an increase of +142.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, vTv Therapeutics Inc.’s cash and equivalents has grown by 4087.0% (from $2.12 million to $88.93 million).
- The most recent figure is from vTv Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: